Seeking Alpha
 

Oculus Innovative Sciences, Inc. (OCLS)

- NASDAQ
  • Thu, Jul. 30, 4:15 PM
    • Oculus Innovative Sciences (NASDAQ:OCLS): FQ1 EPS of -$0.15 misses by $0.05.
    • Revenue of $3.68M (+8.6% Y/Y) misses by $0.28M.
    • Press Release
    | Thu, Jul. 30, 4:15 PM | 1 Comment
  • Fri, Jun. 12, 7:05 AM
    • Oculus Innovative Sciences (OCLS) FQ4 results: Revenues: $4M (+37.9%); COGS: $2M (+33.3%); R&D Expense: $0.4M (-42.9%); SG&A: $3.3M (+17.9%); Operating Loss: ($1.7M) (+9.0%); Net Loss: ($1.5M) (-119.7%); Loss Per Share: ($0.11) (-111.1%).
    • FY2015 results: Revenues: $13.9M (+1.5%); COGS: $6.6M (+24.5%); R&D Expense: $1.5M (-48.3%); SG&A: $12.4M (+6.9%); Operating Loss: ($6.7M) (-9.8%); Net Loss: ($8.2M) (-321.6%); Loss Per Share: ($0.85) (-257.4%); Quick Assets: $6.1M (+10.9%).
    • No guidance given.
    | Fri, Jun. 12, 7:05 AM | Comment!
  • Thu, Jun. 11, 4:10 PM
    • Oculus Innovative Sciences (NASDAQ:OCLS): FQ4 EPS of -$0.11 beats by $0.14.
    • Revenue of $3.98M (+36.8% Y/Y) beats by $0.86M.
    • Press Release
    | Thu, Jun. 11, 4:10 PM | 2 Comments
  • Fri, Feb. 13, 10:50 AM
    • Oculus Innovative Sciences (OCLS -0.6%) FQ3 results: Revenues: $3.2M (-3.0%); COGS: $1.6M (+33.3%); R&D Expense: $0.4M (-50.0%); SG&A: $3.2M (+10.3%); Operating Loss: ($1.9M) (-26.7%); Net Loss: ($5.9M) (-883.3%); Loss Per Share: ($0.69) (-666.7%); Quick Assets: $2.2M (-60.0%).
    • No guidance given.
    | Fri, Feb. 13, 10:50 AM | Comment!
  • Thu, Feb. 12, 4:13 PM
    • Oculus Innovative Sciences (NASDAQ:OCLS): FQ3 EPS of -$0.69 may not be comparable to consensus of -$0.18.
    • Revenue of $3.22M (-2.1% Y/Y) beats by $0.12M.
    • Press Release
    | Thu, Feb. 12, 4:13 PM | Comment!
  • Nov. 13, 2014, 4:13 PM
    • Oculus Innovative Sciences (NASDAQ:OCLS): FQ2 EPS of -$0.08 beats by $0.10.
    • Revenue of $3.3M (-19.3% Y/Y) beats by $0.01M.
    • Press Release
    | Nov. 13, 2014, 4:13 PM | Comment!
  • Aug. 8, 2014, 9:55 AM
    • Oculus Innonvative Sciences (OCLS -2.1%) fiscal Q1 results: Revenues: $3.4M (+0.6%); Operating Expenses: $3.4M (+2.8%); Operating Loss: ($1.5M) (-34.5%); Net Loss: ($70.0K) (+95.9%); Loss Per Share: ($0.01) (+96.2%); Quick Assets: $5.0M (-9.0%).
    • No guidance given.
    | Aug. 8, 2014, 9:55 AM | Comment!
  • Aug. 7, 2014, 4:39 PM
    • Oculus Innovative Sciences (NASDAQ:OCLS): Q2 EPS of -$0.01 beats by $0.16.
    • Revenue of $3.39M (+0.6% Y/Y) beats by $0.26M.
    • Press Release
    | Aug. 7, 2014, 4:39 PM | Comment!
  • Jun. 12, 2014, 4:36 PM
    • Oculus Innovative Sciences (OCLS): FQ4 GAAP EPS of $0.99 may not be comparable to consensus of -$0.21.
    • Revenue of $2.9M (-13.2% Y/Y) misses by $0.52M.
    • Press Release
    | Jun. 12, 2014, 4:36 PM | Comment!
  • Nov. 19, 2013, 4:32 PM
    • Oculus Innovative Sciences (OCLS): FQ2 EPS of -$0.21 misses by $0.06.
    • Revenue of $4.1M beats by $0.07M. (PR)
    | Nov. 19, 2013, 4:32 PM | Comment!
  • Aug. 8, 2013, 6:04 PM
    • Oculus Innovative (OCLS): Q2 EPS of -$0.26 in-line.
    • Revenue of $3.4M misses by $0.28M. (PR)
    | Aug. 8, 2013, 6:04 PM | Comment!
  • Jun. 13, 2013, 6:59 PM
    More on Oculus (OCLS): FQ4 misses across the board. Product revenues, including licensing fees, were flat Y/Y, with increases in Europe, China, India and Singapore offset by declines in the United States and Mexico. The company cites its More Pharma transaction, which reduced short-term revenue growth despite a 49% increase in unit volume sales, and the delayed seasonal purchasing in the ranch and farm animal market of its Vetericyn animal healthcare products due to late winter storms. Shares -1.4% AH.
    | Jun. 13, 2013, 6:59 PM | Comment!
  • Jun. 13, 2013, 4:15 PM
    Oculus (OCLS): Q1 EPS of -$0.44 misses by $0.31. Revenue of $3.34M misses by $0.53M. (PR)
    | Jun. 13, 2013, 4:15 PM | Comment!
  • Feb. 13, 2013, 6:40 PM
    Oculus Innovative Sciences (OCLS): FQ3 EPS of -$0.05 beats by $0.03. Revenue of $3.5M (+27% Y/Y) beats by $0.22M. (PR)
    | Feb. 13, 2013, 6:40 PM | Comment!
Visit Seeking Alpha's
OCLS vs. ETF Alternatives
Company Description
Oculus Innovative Sciences Inc designs, produces and markets prescription and non-prescription products. It provides products for wound management, nursing home & home healthcare, dermatology and wound & skin care for consumers.